The demographic profile confirms patterns familiar from other African series but adds important nuance. The mean age at diagnosis was 36.67 years, with patients ranging from 11 to 70 years old, and the 10-to-30 age group accounted for 41.6 percent of cases. Women dominated overwhelmingly: 77 of the 84 patients were female, producing a sex ratio of 0.09, meaning roughly eleven women for every man. Most patients were married (61.9 percent), worked in the primary sector (88 percent), and came from urban areas (73.8 percent), although a meaningful minority lived in rural or semi-urban surroundings. Half of the patients had experienced symptoms for less than a year before entering the cohort, while 45 percent had lived with the disease for one to five years.

Clinically, the disease showed its characteristic protean face. Joint involvement was the most frequent category, affecting 64.28 percent of patients, followed by mucocutaneous signs at 54.76 percent and general symptoms at 52.38 percent. Within these categories, inflammatory polyarthralgia stood out as the single most common finding, present in 63.1 percent of patients, while physical asthenia affected 47.6 percent. Skin manifestations included erythematosquamous lesions in 16.7 percent of patients and non-specific erythematous lesions in 15.5 percent, with discoid lupus, malar (vespertilio) erythema, alopecia, and Raynaud’s phenomenon each appearing in smaller proportions. Neuromuscular signs affected 20.24 percent of patients, cardiovascular signs 15.48 percent, pleuropulmonary signs 13.10 percent, and digestive signs 7.14 percent.

The laboratory findings underscore both the diagnostic value and the limitations of routine testing in resource-constrained settings. Anemia was the most common hematological abnormality, found in 66.1 percent of patients, followed by elevated C-reactive protein in 36.9 percent and an accelerated erythrocyte sedimentation rate in 20.2 percent. Antinuclear antibodies, measured by indirect immunofluorescence on HEp-2 cells, were positive in 71.4 percent of patients, with titers ranging from 80 to 10,000 IU and a mean of roughly 1,007 IU. The speckled fluorescence pattern predominated at 85.9 percent, far ahead of homogeneous, nucleolar, centromeric, and cytoplasmic patterns. Anti-dsDNA antibodies were detected in 12 percent, anti-Sm in 10.7 percent, and a broad panel of anti-ENA specificities, including anti-Ro52 at 11.9 percent, completed the immunological picture. Skin biopsies revealing the characteristic lupus band were performed in 21 of 22 patients referred from dermatology, supporting the diagnosis in a quarter of the cohort.

Disease activity, quantified with the SLEDAI-2K score, averaged 5.74 on a scale from 0 to 19. Just over half the patients (51.19 percent) had mild activity, 22.62 percent had moderate activity, and 26.19 percent had severe disease. Severe systemic complications were led by cardiac involvement in 9.5 percent of patients, renal involvement in 7.1 percent, and neurological involvement in 5.9 percent. Cardiac events included intracardiac thrombosis, thrombophlebitis, heart failure, and pericarditis, while renal manifestations ranged from isolated proteinuria to renal insufficiency requiring ongoing nephrology care after a biopsy confirmed diffuse stage IV glomerulonephritis in one patient. Neurological presentations included altered mental status, psychosis, and coma.

The study also documented the overlap phenomenon that complicates lupus diagnosis worldwide. Six patients carried a concurrent diagnosis of rheumatoid arthritis, the most frequent association in the cohort, followed by two patients each with antiphospholipid syndrome, multiple autoimmune syndrome, and systemic scleroderma. Single cases of Sjögren’s disease and combined scleroderma-rheumatoid arthritis were also recorded. Two patients had childhood-onset lupus, aged 11 and 15, both presenting with distinct dermatological manifestations including malar erythema and characteristic histopathological features. Notably, the authors observed that lupus beginning at an older age tended to present with greater disease severity and more cardiopulmonary complications.

Treatment reflected the realities of a regional hospital working with limited resources. Hydroxychloroquine, the immunomodulator that forms the backbone of lupus therapy worldwide, was prescribed to 88 percent of patients, while azathioprine was used in 7.14 percent. A small number of patients received additional agents, including corticosteroid boluses, oral anticoagulants, and supportive medications. The authors note that hydroxychloroquine reduces the risk of disease flares, allows lower corticosteroid doses, and helps prevent lupus-related thromboembolic disease, and that it is not contraindicated during pregnancy. Access to newer biologic therapies, such as anti-interferon agents and monoclonal antibodies like belimumab and rituximab, remains limited in Africa, where high cost restricts widespread use.

Statistical analysis revealed a striking observation: all cases of cardiac complications occurred in female patients, although the association between sex and cardiac involvement did not reach statistical significance (OR 2.59, 95 percent CI 0.13 to 49.5, p = 0.59). The authors attribute the wide confidence interval to the small number of events and the marked imbalance between sexes. Disease severity, by contrast, appeared more closely linked to delayed diagnosis and was more commonly observed in women, though this too fell short of statistical significance (p = 0.18).

The findings align closely with other West and Central African studies. The prevalence of 0.15 percent sits below the 0.27 percent reported by Daou and colleagues across three hospitals in Niamey, Niger, and well below the 2.19 percent reported by Camara and colleagues over five years in Abidjan, a difference the authors attribute to their larger overall study population. The mean age of 36.67 years is consistent with the 33.9 years reported by Fall and colleagues in Dakar in 2011 and the 35 years found by Camara in Abidjan. The predominance of joint and skin symptoms mirrors patterns documented in Mali by Gassama and colleagues and in Cameroon by Bija and Eloundou and their teams, where polyarthritis and cutaneous signs consistently top the list of presenting features.

The study’s limitations are candidly acknowledged. Its retrospective design, the lack of digitized medical records, and incomplete documentation mean some information may have been inaccurately captured. The resource constraints of the setting also meant that patients could not always afford the full range of tests or medications their conditions required. Yet the authors argue that these very constraints make the findings more valuable, because they document lupus as it actually presents in decentralized African healthcare rather than in specialized referral centers. Their conclusion is a call to action: lupus remains a multifaceted condition that is too often misdiagnosed, confused with endemic tropical diseases whose symptoms overlap with its own, and they recommend ongoing training for healthcare personnel alongside therapeutic education sessions for patients to close the diagnostic gap.

Subject of Research: Epidemiology and clinical presentation of systemic lupus erythematosus in a decentralized hospital setting in Senegal

Article Title: Epidemiological and diagnostic characteristics of systemic lupus erythematosus in a decentralized setting in sub-Saharan Africa

Article References: Diallo, B. M., Bacourine, S., Dione, H., Sow, A., Berthe, A., Toure, P. S., Diop, M. M., & Ka, M. M. (2026). Epidemiological and diagnostic characteristics of systemic lupus erythematosus in a decentralized setting in sub-Saharan Africa. Frontiers in Lupus, 4, Article 1924447. https://doi.org/10.3389/flupu.2026.1924447

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1924447

Keywords: systemic lupus erythematosus, Senegal, sub-Saharan Africa, autoimmune disease, epidemiology, SLEDAI-2K, hydroxychloroquine, antinuclear antibodies, diagnostic delay, rheumatology, Tivaouane, lupus nephritis

The study team, led by Mehrnaz Adib and Payman Sadeghi, enrolled 171 neonates between March 2023 and March 2024 at a single center. Crucially, they deliberately excluded babies whose mothers had active or newly diagnosed autoimmune disease, or who had experienced a disease flare during pregnancy. That design choice is what makes the study distinctive: most existing knowledge about neonatal ANA positivity comes from high-risk pregnancies where mothers have known conditions such as lupus or Sjögren’s syndrome, and where antibodies like anti-Ro/SSA can cause congenital heart block and neonatal lupus rashes. By focusing on a clinically lower-risk population, the researchers asked a more fundamental question: how often does cord blood from apparently unremarkable pregnancies test positive for antinuclear antibodies, and does that positivity translate into any detectable illness?

The technical backbone of the study was the indirect immunofluorescence assay, or ANA-IFA, performed on human epithelial type 2, or HEp-2, cells. This method remains the gold standard for ANA detection because it exposes the patient’s serum to whole cells and lets trained observers see exactly where fluorescently labeled antibodies bind within the nucleus. The assay is broad by design; it detects reactivity against many nuclear antigens at once, which makes it sensitive but not specific for any particular disease. Out of 171 cord-blood samples, 26 came back positive, a prevalence of 15.2 percent, with an exact 95 percent confidence interval ranging from 10.2 to 21.5 percent. In other words, roughly one in six newborns in this low-risk cohort carried detectable antinuclear reactivity at birth.

That number alone is striking, but the researchers went further. Each ANA-IFA-positive infant was then subjected to a multiparameter antigen-specific antibody panel, a line-immunoassay approach that probes for reactivity against individual molecular targets. Only four of the 26 positive infants, or 15.4 percent, showed reactivity on this finer-grained panel. All four carried antibodies against double-stranded DNA, a target classically associated with systemic lupus erythematosus. Two also had anti-histone antibodies, and single infants showed reactivity against anti-nucleosome, anti-Jo-1, and anti-Ro52. Notably, none of the infants had reactivity against Ro60 or La/SSB, the two antigens most tightly linked to congenital heart block and neonatal lupus when transferred across the placenta. The absence of those particular specificities is perhaps the single most clinically comforting detail in the entire dataset.

All 26 ANA-IFA-positive infants then underwent a protocol-driven evaluation that most newborn screening programs would consider exhaustive. It included hematologic assessment with complete blood counts, liver enzyme measurement, electrocardiography, echocardiography, and structured clinical examination, repeated through the first 12 months of life. The results were remarkably benign. Four infants showed transient elevations in liver enzymes, specifically alanine and aspartate aminotransferases, but these abnormalities normalized within a single month and were not accompanied by any other signs of disease. Beyond that, no clinically relevant autoimmune manifestations were detected in any of the 26 positive infants, giving a rate of zero out of 26, with an exact 95 percent confidence interval of 0.0 to 13.2 percent. Hearts were structurally normal on echocardiography, conduction was normal on electrocardiography, and blood counts stayed within expected ranges.

The 145 ANA-IFA-negative infants received routine clinical follow-up, with investigations ordered only when symptoms warranted. None was recorded as developing autoimmune manifestations during the first year, but the authors are careful to acknowledge an important asymmetry in their design: because the negative group did not undergo systematic laboratory and cardiac screening, subclinical abnormalities in that group cannot be formally excluded. This differential outcome ascertainment, where positive infants were scrutinized far more intensively than negative ones, is a standard feature of such exploratory designs but limits how confidently the two groups can be compared. It is one of several caveats the researchers list when explaining why their findings cannot yet be turned into firm risk estimates.

The maternal side of the equation adds another layer of complexity. Mothers of the 26 positive infants underwent ANA-IFA testing themselves, and three of the 26 came back positive. Intriguingly, all three of those mothers had infants with antigen-specific panel reactivity, suggesting some degree of mother-to-infant concordance in antibody profiles, exactly what one would expect if placental transfer were the source of the cord-blood signal. However, antigen-specific testing of the mothers was incomplete, which prevented the team from performing a comprehensive concordance analysis. Without paired, complete maternal and neonatal panels, it remains impossible to say definitively whether every cord-blood ANA reflects passive maternal transfer, fetal immune activity, or some mixture of both. The authors also note that limited run-level assay documentation constrains the interpretability of individual results.

What, then, should clinicians and anxious parents take away from this work? The authors are explicit: these findings do not support routine ANA-IFA testing of asymptomatic neonates, and they do not justify any change to established surveillance protocols for babies with confirmed maternal anti-Ro/SSA or anti-La/SSB exposure. The reason is straightforward. Cord-blood ANA positivity in a low-risk population turns out to be relatively frequent, roughly 15 percent, but almost entirely nonspecific, and in this cohort it carried no measurable clinical consequence within the first year. Screening every newborn would therefore generate a substantial number of positive results, trigger extensive and costly workups, and create parental anxiety, all in pursuit of a signal that, on current evidence, rarely means anything. The transient liver enzyme elevations seen in four infants resolved without intervention and did not correspond to any antigen-specific pattern of obvious concern.

The study’s limitations are candidly enumerated and worth understanding. Beyond the differential ascertainment between positive and negative infants, the sample size of 171, while respectable for an exploratory single-center cohort, is too small to detect rare outcomes such as congenital heart block, which occurs in only a small fraction of anti-Ro-exposed pregnancies even in high-risk populations. The single-center design means the findings may not generalize to populations with different genetic backgrounds, referral patterns, or assay practices. And the twelve-month follow-up window, though it covers the period when neonatal lupus manifestations typically appear, cannot speak to longer-term risks of autoimmunity that might emerge in childhood or later.

For that reason, the research team calls for larger multicenter studies with paired maternal-neonatal testing, uniform assessment protocols, documented assay runs, serial antibody measurements over time, and follow-up extending well beyond infancy. Such work would settle whether the 15 percent of newborns with cord-blood ANA reactivity represent a truly silent majority whose antibodies simply fade as maternal immunoglobulin is catabolized over the first months of life, or whether a small subset harbors a subtle signal that only longer observation can reveal. Until then, this study provides a valuable baseline: in babies born without any hint of maternal autoimmune disease, antinuclear antibodies in cord blood are common, their antigen-specific signatures are uncommon, and clinically meaningful illness in the first year of life appears to be vanishingly rare. The placenta, it seems, delivers far more reassurance than alarm.

Subject of Research: Cord-blood antinuclear antibody positivity and first-year clinical outcomes in newborns without maternal autoimmune disease

Article Title: Cord-blood ANA-IFA positivity and first-year clinical findings in a selected lower-risk population: an exploratory prospective cohort study

Article References: Adib, M., Sheykhian, T., Assari, R., Alimadad Tafreshi, A., Ashkboos, K., Raeeskarami, S. R., Ziaee, V., Habibi, A., & Sadeghi, P. (2026). Cord-blood ANA-IFA positivity and first-year clinical findings in a selected lower-risk population: an exploratory prospective cohort study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07735-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07735-0

Keywords: antinuclear antibodies, cord blood, neonates, autoimmunity, ANA-IFA, HEp-2 cells, anti-dsDNA, neonatal lupus, anti-Ro/SSA, cohort study, pediatrics, placental antibody transfer